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Abstract  26 
 27 
Background: Sri Lanka has a high prevalence of -thalassaemia major. Clinical management 28 
is complex and long-term and includes regular blood transfusion and iron chelation therapy. 29 
The economic burden of β-thalassaemia for the Sri Lankan healthcare system and households 30 
is currently unknown. 31 
Methods: A prevalence-based, cost-of-illness study was conducted on the Thalassaemia Unit, 32 
Department of Paediatrics, Kandy Teaching Hospital, Sri Lanka. Data were collected from 33 
clinical records, consultations with the head of the blood bank and a consultant paediatrician 34 
directly involved with the care of patients, alongside structured interviews with families to 35 
gather data on the personal costs incurred such as those for travel.  36 
Results: Thirty-four children aged 2-17 years with transfusion dependent thalassaemia major 37 
and their parent/guardian were included in the study. The total average cost per patient year to 38 
the hospital was $US 2601 of which $US 2092 were direct costs and $US 509 were overhead 39 
costs. Mean household expenditure was $US 206 per year with food and transport per 40 
transfusion ($US 7.57 and $US 4.26 respectively) being the highest cost items. Nine (26.5%) 41 
families experienced catastrophic levels of healthcare expenditure (>10% of income) in the 42 
care of their affected child. The poorest households were the most likely to experience such 43 
levels of expenditure.  44 
Conclusions: β-thalassaemia major poses a significant economic burden on health services 45 
and the families of affected children in Sri Lanka. Greater support is needed for the high 46 
proportion of families that suffer catastrophic out-of-pocket costs. 47 
 48 
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Background  51 
 52 
-thalassaemia major is Sri Lanka’s most common serious single gene disorder with an 53 
estimated prevalence of 2.2%12. Medical advances in recent decades have transformed this 54 
inherited haemoglobinopathy from a severe, life-limiting disease to a treatable chronic 55 
condition. With high quality of care, patients can expect a near-normal life as fully integrated, 56 
industrious members of society3.  57 
 58 
The lifelong treatment regime for -thalassaemia major comprises regular (usually monthly) 59 
blood transfusion and iron chelation therapy (ICT) 2. However, despite ICT, transfusional iron 60 
overload causes many complications affecting organ systems such as the liver, endocrine 61 
organs and heart. Cardiac complications, including pericarditis and dilated cardiomyopathy, 62 
still represent 71% of the cause of death in thalassaemic patients 3. Regular clinic appointments 63 
are used to screen for complications including the use specialist equipment such as ultrasound, 64 
slit-lamps, audiograms and blood glucose monitoring devices. Blood tests also include 65 
serological testing for HIV and hepatitis viruses. The screening and clinical management of 66 
these complications requires a specialised multidisciplinary team approach. During hospital 67 
care, associated health-care costs include non-medical personnel, staff transport, supplies and 68 
requisites, maintenance, electricity, water, food, contractual services and other recurrent 69 
expenditure.  70 
 71 
Cost-of-illness (COI) studies aim to measure the total societal costs of a disease. Total societal 72 
costs extend beyond those related to health care to include household expenditures, and in some 73 
studies, lost productivity associated with employment.  An important concept related to COI 74 
studies is the “cost burden” of a disease, which refers to household cost expressed as a 75 
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percentage of household income. A common approach to measuring economic hardship 76 
associated with health payments is to define a ‘catastrophic’ spending level of >10% of 77 
household income. This degree of cost burden is considered to directly impact consumption of 78 
basic needs such as food and education or trigger the sales of assets leading to higher levels of 79 
debt or poverty6–8. 80 
 81 
We identified 14 COI studies of thalassaemia, published between 1975-2017, in Canada, India, 82 
Iran, Israel, Italy, Myanmar, Taiwan, Thailand and the UK4,9–21. Reported medical costs to 83 
health services ranged from $US 873 to almost $40,000 per patient year10,15. In Sri Lanka, the 84 
national blood transfusion service is provided by the Ministry of Health and comprises 98 85 
hospital-based blood banks and there are two standalone thalassaemia centres. De Silva et al. 86 
estimated in 2000 that the cost of preparing blood, ICT, essential investigations and hospital 87 
visits was LKR 175,000 (equivalent to $US 2,465)2. This estimate is now outdated in view of 88 
substantial changes to patient care.  89 
 90 
The costs of thalassaemia do not just fall on the health service but also on the affected 91 
individual and their household as treatment decisions and coping mechanisms usually occur at 92 
the household level22. Seven of the economic analyses assessed costs to the 93 
household4,10,12,13,18,20,21 but none assessed the cost burden. No assessment of the costs to 94 
families was undertaken in the study in Sri Lanka2. We undertook a prevalence based, cost-of-95 
illness study to provide an updated estimate of the economic burden to both the health service 96 
and families of transfusion dependent -thalassaemia in children in Sri Lanka. Health service 97 
costs include both direct hospital costs, which are directly related to patient care such as staff 98 
costs, and indirect hospital costs, such as overheads.  Household costs include items such as 99 
travel and food costs when attending treatment centers. 100 
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 101 
Methods  102 
Study location  103 
This study was undertaken in Kandy Teaching Hospital (KTH) in the Central province of Sri 104 
Lanka. KTH, the second largest medical institution in the country, has two main paediatric 105 
wards with a capacity of 100 beds and a single integrated 8 bedded blood transfusion unit. As 106 
well as patients living in the hospital catchment area, many patients from adjoining districts 107 
attend for specialised medical care such as thalassaemia management. In 2017 there was over 108 
22,000 admissions to KTH including almost 8,000 paediatric cases23.  109 
 110 
Patients 111 
The inclusion criteria were children (<18 years) with a diagnosis of -thalassaemia major who 112 
had attended KTH for at least one year. All children who attended for blood transfusion during 113 
the period of 12th June – 11th of July 2017 were invited to take part in the study. In order to 114 
estimate the mean cost of the patients and assuming a normal distribution, we aimed to recruit 115 
at least 30 cases as directed by the Central Limit Theorem24. 116 
 117 
Collection of demographic and clinical data 118 
At the time of blood transfusion, demographic data and the number of transfusions and units 119 
of blood received, investigations and drug treatment over the preceding 12 months was 120 
extracted from case records.  121 
Estimating health service costs 122 
Costs were estimated for both in-patient care and attending out-patient clinics. Staff costs per 123 
inpatient day were calculated using estimates of workload intensity25. Staff costs were allocated 124 
to individual patients based on the complexity of their care needs categorised according to a 125 
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four point scale, with each category representing a measure of workload intensity (Table 1).  126 
Patients were allocated to the scale by the doctors working on the relevant wards.  127 






Patients who require less than average care E.g. Regular 
transfusion visits 
1 1 
Sub-acute patients who require the standard level of care 2 2.5 
Acute patients who require more than average care  3 3.5 
Intensive care patients who require a high level of care  4 7 
 129 
A breakdown of monthly overhead spending for the hospital was provided by the accounting 130 
staff. Direct hospital costs were then inflated to take into account the indirect costs of care 131 
using the mark-up method26. With this method, the ratio of indirect to direct costs is calculated 132 
based on available budget information, then used to adjust the direct costs associated with the 133 
patient population of interest (and for which indirect cost information is not available) 134 
providing an estimate of the total hospital cost (direct + indirect). 135 
The equipment used for monitoring for complications was not exclusively used in the care of 136 
thalassaemic patients; therefore, we estimated the cost per test of using such equipment. The 137 
price of equipment along with its estimated life expectancy was used to calculate the equipment 138 
cost per test.   The cost per month of equipment (mE) was calculated using the formula mE =139 
cE
L
  , where cE is the purchase price of equipment and L is the life expectancy in months. The 140 
cost per test (C) was calculated using the formula C =
mE+ sW
n
, where sW is the monthly staff 141 
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wages required to run the clinic and n is the total number of tests performed in 1 month. Table 142 
2 summarises the resource consumption and measurement.  143 
 144 
Table 2 - Summary of resource consumption 145 
Resource Measure  Source of data  Valuation 





Time spent  
Number and types 





Blood bank  
 
Salary  
Price per item 
Drug therapy  
- ICT  
- Concomitant      
medication 
 
Dose and frequency 
 
Patient records  
Pharmacy department 
 
Price per item  
Clinic and 
outpatient 
- Staff  
- Equipment  
 
 
Number of type  
 
 





Cost per test  
Overheads 
 
Number of items of 
shared services 
Accounting department  Price per item  
Household costs 
- Transport and 
food  
 
Expenditure per visit  
 




Estimating household costs 147 
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Structured interviews were conducted with children and their parents/guardians in the local 148 
language by a trained research assistant (see interview guide in Additional file 1). We expressed 149 
household health expenditure per month as a percentage of total monthly household income27–150 
30. 151 
 152 
Statistical analysis  153 
Descriptive statistics were used to summarise the participants and cost items. Mean (SD) was 154 
used for normally distributed data and median (IQR) for non-normal data. A Pearson 155 
correlation test was used for analysis and P-value <0.05 for statistical significance. 156 
 157 
Results  158 
All participants who were invited to join the study agreed to take part and a total of 34 children 159 
attending for blood transfusion were enrolled. Median age was 10.0 years (range 2.3-17.0 160 
years) and 22 (64.7%) were female. Median (range) age at first transfusion was 4 (1-13) months 161 
(age not available for one child).  162 
 163 
Direct Hospital Costs 164 
Blood transfusion and ICT 165 
Median (range) number of transfusion sessions per year was 12.0 (11.0-14.0) and the median 166 
(IQR) number units of units transfused per year was 21.0 (18.5-23.0). The cost of preparing 1 167 
unit of blood was $US 44 (personal communication; Head of the Blood Bank, KTH) resulting 168 
in an average cost of $US 893 per patient year for blood transfusions. 169 
 170 
26 (76.5%) patients received oral deferasirox, 1 (2.9%) IV deferoxamine and 7 (20.1%) 171 
combined ICT including transition from oral to IV treatment. During the 12 months studied, 172 
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27 patients remained on a stable dose of ICT whilst 7 patients changed either their dose or ICT 173 
agent at least once. The cost of oral deferasirox 100mg and 400mg was $US 0.61 and $US 1.34 174 
respectively and IV deferoxamine 500mg cost $US 3.04. On average, ICT cost was mean (SD) 175 
$US 967.3 (651.7) per patient year. The average cost of concomitant medication was mean 176 
(SD) $US 5.10 (7.2) per patient year. ICT accounted for 99.5% of the total drug costs.  177 
 178 
Staff  179 
The paediatric team was composed of 1 Consultant, 1 Senior Registrar, 3 Registrars, 4 Senior 180 
House Officers, 4 House Officers, 1 Sister and 17 Nurses. The combined monthly salary of 181 
these staff was $US 14,126. The total workload units were 107 which gives a staff cost of $US 182 
4.34 per workload unit. Patients remained on the ward for a mean (SD) of 2.1 (0.54) days per 183 
admission and this amounts to an average staff cost of $US 114 per patient year.  184 
 185 
Investigations and clinic visits 186 
The number of investigations, costs per unit and cost per patient year of each investigation 187 
were combined with clinic attendance costs; totalling $US 3,832 equivalent to $US 113 per 188 
patient year.  189 
 190 
Age positively correlated with treatment cost (p-value<0.001) (Figure 1) reflecting the 191 
increased transfusion and ICT requirements in older children with an increase of $US 112 for 192 
every 1year increase in age. 193 
 194 
Figure 1 - Relationship between age and direct hospital costs. y = 112.07x + 1060.8 195 
R² = 0.3748. Pearsons correlation co-efficient = 0.64 196 
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 197 
Indirect Hospital Costs  198 
Overhead and building  199 
 The total indirect costs were $US 389,510 and the total direct costs borne by the hospital were 200 
$US 1,600,910 giving a mark-up percentage of 24.3%.  This equates to an additional $US 509 201 
per patient year in overhead costs.  202 
 203 
Household Costs 204 
In 31 (91.2%) children, the mother provided information, the grandmother in 2 (5.8%) and the 205 
father in 1 (2.9%). The highest educational level for household head was primary for 6 (17.6%), 206 
secondary for 24 (70.6%) and graduate for 3 (8.8%; not reported for 1 child). Four (11.8%) of 207 
the respondents were self-employed, 1 (2.9%) was employed and 29 (85.3%) reported 208 
housework as their occupation.  209 
Total household costs were $US 206 per year with food and transport ($US 99 and $US 51 210 
respectively) being the highest cost items. Two patients reported hospitalisation in the past 12 211 
months; 1 for 15 days and 1 for 4 days with a household cost of $US 164 and $US 3 respectively 212 
which was included in the household costs. The other cost items measured can be found in the 213 
supplementary file. Eight children were too young to attend school and the remaining 26 214 
reported median (range) of 37.5 (24-84) days of absence from school per year.  215 
 216 
Household Cost Burden 217 
Mean (SD) household annual income was $US 2,548 (1340). One household reported no 218 
income being dependent on bank loans and was excluded from the cost burden calculations as 219 
their income denominator was 0. Figure 2 shows that cost burden varied between income 220 
quartiles.  Only 1 household had a low-cost burden and 9/33 (27.3%) experienced a 221 
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catastrophic cost burden despite the free medical care available in Sri Lanka. Households in 222 
the lowest income quartile experienced a median cost burden of over 10% which is often 223 
regarded as ‘catastrophic’6–8. Of households in the lowest income quartile, cost burdens were 224 
either high (N=2) or catastrophic (N=5) 225 
 226 
In total 5 families took out a loan to help cover the costs generated by their child’s thalassaemia.  227 
Of these 4 out of 5 were in the lowest income quartile (one was in the second highest).  228 
 229 
 230 
Figure 2 – Relationship between income quartile and cost burden. Boxes show Median and 231 
IQR, whiskers show range.  232 
 233 
 234 
Total costs  235 
The total annual direct hospital cost was $US 2092 per patient year. This figure was inflated 236 
accordingly by the mark up of 24%, which amounts to $US 2601 per patient year. Household 237 
costs were $US 206. This amounts to a total societal burden of $US 2807 per patient year. 238 
Figure 3 reports the breakdown of total societal cost expressed as a percentage. As shown BT-239 
ICT makes up the 66% of the total cost.  240 
 241 
Figure 3 – Total societal cost. Values are reported in $US and expressed as a percentage of 242 
the total societal cost 243 
 244 
Discussion  245 
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This cost-of-illness study of transfusion dependent -thalassaemia major in children in Sri 246 
Lanka includes a comprehensive assessment of direct and indirect costs to the healthcare 247 
system and costs to household budgets. We estimated that the healthcare costs of managing 248 
thalassaemia are approximately $US 2,601 per patient year. In addition, despite free healthcare 249 
in Sri Lanka, households frequently spend over 10% of their annual income on blood 250 
transfusion sessions, follow up tests, special foods and hospitalisation; with those most likely 251 
to spend this ‘catastrophic’ level being from the lowest income quartile.  252 
The only previous economic analysis in Sri Lanka, published in 2000, estimated an annual cost 253 
of treating thalassaemia of  LKR 175,000 ($US 2,465) per patient year2. When inflated by the 254 
consumer price index provided by the World Bank31 this value is $US 10,649 at present day 255 
value. One potential cause for this lower cost is in the change in the drug of choice for ICT 256 
from a sub-cutaneous infusion of deferoxamine to oral deferasirox. Deferasirox is considerably 257 
cheaper than IV deferoxamine at current pharmacy prices (500mg = $US 1.96 vs 3.06; costs 258 
provided by the pharmacy department) and does not require an infusion pump for 259 
administration. Other advances in medical care likely also contribute to this lower estimate. 260 
The International Diabetes Federation (IDF) estimated the cost of managing diabetes in Sri 261 
Lanka at $US 185 per patient year in 201732. This means we estimate the annual direct hospital 262 
cost of thalassaemia in children ($US 2092) to be over 10 times that of an adult diabetic patient.  263 
 264 
Factors accounting for the variation in costs in previous studies4,9,18–21,10–17 included age of the 265 
patients, treatment regimen and the number of complications. Differences in study design  266 
included the use of hypothetical patients and which costs were included such as productivity 267 
loss and those related to complications. Costs varied considerably between studies conducted 268 
in the same country. For example In Iran, the cost per patient year ranged from $1730 to  269 
$832120,21. This highlights the disparities in methods of cost assessment including the use of 270 
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assumptions related to treatment patterns, patient sample, overhead allocation method, local 271 
unit costs and data collection methods; all of these factors limit the scope for inter study 272 
comparison. The use of a standard set of reporting guidelines as recommended for cost-273 
effectiveness studies33 would ensure that studies capture similar costs and enable better inter-274 
study comparison. 275 
 276 
The true economic impact of a disease must consider factors beyond health related 277 
expenditures, such as family coping strategies and impact on future livelihood22. In severe 278 
poverty, where a household struggles to achieve minimum food or fuel levels, even a small 279 
change (e.g. the loss of one day’s wage) may have substantial implications for the wellbeing 280 
of the whole household requiring drastic coping strategies6. Family strategies often aim to 281 
maintain short-term economic sustainability for the household34 but the selling of assets or 282 
borrowing of money to help with treatment clearly generate future challenges and costs. The 283 
relatively low levels of household income in our study resulted in about 1 in 4 households 284 
experiencing catastrophic costs (>10% of total income).  Of the 5 families who took out a loan 285 
to help cover the costs of thalassaemia, 4 were from family or neighbours exemplifying the 286 
bonding / bridging forms of social capital, and the greater need for the poorest families to utilise 287 
family networks and assets compared to families with more resources35. To further understand 288 
the complex dynamics of household expenditure on healthcare and the impact of lost schooling 289 
for individuals, longitudinal in-depth quantitative and qualitative research that assesses 290 
expenditure and future income implications is needed. A greater understanding of coping 291 
methods and how assets are mobilised is necessary to assess the impact on household 292 
livelihoods. We found out-of-pocket costs were not associated with household income (Pearson 293 
coefficient 0.21, p-value 0.20). Since the out-of-pocket payments contained mainly transport 294 
and food costs, the observed correlation was not unexpected. Our results indicate that there are 295 
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discrepancies between household cost burden across income quartiles, despite the free medical 296 
care available in Sri Lanka. However, we were unable to adequately investigate spending 297 
patterns and no data were collected on household’s ability to pay for basic needs after the cost 298 
of healthcare had been taken out. Studies that explore how households prioritise expenditure, 299 
how they perceive basic needs, and the factors which underpin inequality and financial 300 
protection would help generate a more complete picture.  301 
 302 
Strengths and limitations 303 
The study estimated the costs of managing β-thalassaemia major both for health services and 304 
households. We recruited children of diverse ages, socioeconomic backgrounds and healthcare 305 
requirements to provide a broad view of costs to households. However, the data relate only to 306 
children in one specific healthcare setting; conducting the study in more than one hospital site 307 
and recruiting a greater sample size, would improve validity and generalisability especially as 308 
distance from treatment facilities and, therefore, transport costs may differ amongst regions. 309 
This additional information would be important when considering policy implications at the 310 
national level. In 2016, the median income in Kandy was 42000Rs compared with a national 311 
median of 44000Rs as reported by the Department of Census and Statistics36. Kandy was the 312 
4th richest of 25 districts in this census data with the national median somewhat skewed by 313 
Colombo which has a median of 70,000Rs. Therefore, we consider that the economic status of 314 
the Kandy population is approximately representative of the national population outside of 315 
Colombo. 316 
 317 
When calculating the mark-up percentage, sufficient data were not available to determine 318 
whether certain cost centres were utilised by the patients in our study. The high cost of 319 
medication for ICT is unlikely to have a linear correlation with overhead costs as assumed 320 
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when using the marginal mark-up methodology. This means the mark-up percentage may be 321 
an over-estimate of the actual value. On the other hand, the cost of administrative, domestic 322 
and pharmacy staff were not included in the overall staff cost. A study of administrative costs 323 
in 8 nations reported administrative costs make up between 12% and 25% of total hospital 324 
costs37.  325 
 326 
In this study, costs were only estimated over a one-year period. Longer periods of observation 327 
are needed to get a more accurate view of costs and to quantify the long-term consequences of 328 
thalassaemia. This is of particular importance in thalassaemia due to the increasing cost with 329 
age as demonstrated in other studies. Using an incidence-based approach (which includes costs 330 
throughout a patient’s lifetime) would be more useful in policy decision making where 331 
preventative measures are considered as it provides a more accurate level of saving. Also, 332 
incidence-based studies allow an analysis of the disease throughout the life-course allowing 333 
researchers to develop improved clinical and therapeutic guidelines for disease management. 334 
 335 
Finally, we did not attempt to estimate the cost of the potential impact that loss of education 336 
could have on future financial capabilities and acquisition of household human capital38. A 337 
study comparing adult employment and income in people with -thalassaemia and those 338 
without would be required. This could then be applied to the number of adults with -339 
thalassaemia in a prevalence-based COI study. 340 
 341 
Conclusion 342 
Managing thalassaemia cost the healthcare system in Sri Lanka an estimated $US 2601 per 343 
patient year. Most of this total cost can be attributed to blood transfusion and ICT. Despite free 344 
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healthcare, many households incurred catastrophic costs. Many families caring for a child with 345 
-thalassaemia require financial support to mitigate adverse financial hardship. 346 
 347 
Declarations  348 
Ethical approval was granted by Kandy Teaching Hospital and Sheffield University ethics 349 
committees. Informed consent was obtained from participant´s parents.  350 
Consent for publication – Not Applicable  351 
Availability of data – The datasets analysed during the current study are available on request 352 
from the corresponding author. 353 
Competing interests - The authors declare that they have no competing interests 354 
Funding – The research was self-funded and was in fulfilment of the lead authors Masters of 355 
Public Health and International Development degree at the University of Sheffield, Sheffield, 356 
UK.  357 
Authors contributions –  HRE and SA designed the study. The study was coordinated by 358 
HRE, SA, and MA. HRE and BNM collected the data. Analysis and interpretation of the data 359 
was conducted by HRE. The manuscript was drafted by HRE, SD and SA. All authors critically 360 
reviewed and have given final approval of the manuscript. 361 
Acknowledgements – N/A 362 
 363 
References  364 
1.  Premawardhena A, de Silva S, Arambepola M, Olivieri N, Merson L, Muraco J, et al. 365 
Thalassemia in Sri Lanka: A progress report. Vol. 13, Human Molecular Genetics. 366 
2004.  367 
2.  de Silva S, Fisher C, Premawardhena A, Lamabadusuriya S, Peto T, Perera G, et al. 368 
Thalassaemia in Sri Lanka: implications for the future health burden of Asian 369 
 17 
populations. Lancet. 2000;355(9206):786–91.  370 
3.  Mohamed SY. Thalassemia major: Transfusion and chelation or transplantation. 371 
Hematol Oncol Stem Cell Ther. 2017;  372 
4.  Scalone L, Mantovani LG, Krol M, Rofail D, Ravera S, Bisconte MG, et al. Costs, 373 
quality of life, treatment satisfaction and compliance in patients with beta-thalassemia 374 
major undergoing iron chelation therapy: the ITHACA study. Curr Med Res Opin. 375 
2008;24(7):1905–17.  376 
5.  Kremastinos DT, Farmakis D, Aessopos A, Hahalis G, Hamodraka E, Tsiapras D, et 377 
al. β-thalassemia cardiomyopathy: History, present considerations, and future 378 
perspectives. Circ Hear Fail. 2010;  379 
6.  Russell S. Can households afford to be ill? The role of the health system, material 380 
resources and social networks in Sri Lanka. PhD Thesis, Heal Policy Unit Dep Public 381 
Heal Policy. 2001;  382 
7.  Waters HR, Anderson GF, Mays J. Measuring financial protection in health in the 383 
United States. Health Policy (New York). 2004;69(3):339–49.  384 
8.  Goudge J, Gilson L, Russell S, Gumede T, Mills A. The household costs of health care 385 
in rural South Africa with free public primary care and hospital exemptions for the 386 
poor. Trop Med Int Heal. 2009 Apr;14(4):458–67.  387 
9.  Bonifazi F, Conte R, Baiardi P, Bonifazi D, Giordano P, Giannuzzi V, et al. Pattern of 388 
complications and burden of disease in patients affected by beta thalassemia major. 389 
2017;7995(July).  390 
10.  Riewpaiboon A, Nuchprayoon I, Torcharus K, Indaratna K, Thavorncharoensap M, 391 
Ubol B. Economic burden of beta-thalassemia/Hb E and beta-thalassemia major in 392 
Thai children. BMC Res Notes. 2010;3(1):29.  393 
11.  Ghotbi N, Tsukatani T. An economic review of the national screening policy to 394 
 18 
prevent thalassemia major in Iran. 2002;(562).  395 
12.  Aung Myo Han, Khin Ei Han, Thein Thein Myint. Thalassemia in the outpatient 396 
department of the Yangon Children’s Hospital in Myanmar: cost analysis of the day-397 
care-room services for thalassemia. Southeast Asian J Trop Med Public Health. 398 
1992;23(2):273–7.  399 
13.  Mallik S, Chatterjee C, Mandal K, Sardar C, Ghosh P, Manna N. Expenditure to treat 400 
thalassaemia: an experience at a tertiary care hospital in India. Iran J Public Health. 401 
2010;39(1):78.  402 
14.  Weidlich D, Kefalas P, Guest JF. Healthcare costs and outcomes of managing b-403 
thalassemia major over 50 years in the United Kingdom. Transfusion. 404 
2016;56(5):1038–45.  405 
15.  Koren A, Profeta L, Zalman L, Palmor H, Levin C, Zamir RB, et al. Prevention of ?? 406 
Thalassemia in Northern Israel - A cost-benefit analysis. Mediterr J Hematol Infect 407 
Dis. 2014;6(1).  408 
16.  Ho W-L, Lin K-H, Wang J-D, Hwang J-S, Chung C-W, Lin D-T, et al. Financial 409 
burden of national health insurance for treating patients with transfusion-dependent 410 
thalassemia in Taiwan. Bone Marrow Transplant. 2006;37(6):569–74.  411 
17.  Karnon J, Zeuner D, Brown J, Ades A, Wonke B, Modell B. Lifetime treatment costs 412 
of b -thalassaemia major. Clin Lab Haem. 1999;21:377–85.  413 
18.  Ginsberg G, Tulchinsky T, Filon D, Goldfarb  a, Abramov L, Rachmilevitz E a. Cost-414 
benefit analysis of a national thalassaemia prevention programme in Israel. J Med 415 
Screen. 1998;5(3):120–6.  416 
19.  Ostrowsky JT, Lippman A, Scriver CR. Cost-benefit analysis of a thalassemia disease 417 
prevention program. Am J Public Health. 1985;75(7):732–6.  418 
20.  Rezaei S, Karami Matin B, Hajizadeh M. Economic burden of thalassemia major in 419 
 19 
Iran, 2015. Vol. 16, Journal of Research in Health Sciences. 2016. p. 233–4.  420 
21.  Sattari M, Sheykhi D, Nikanfar A, Pourfeizi AH, Nazari M, Dolatkhah R, et al. The 421 
Financial and Social Impact of Thalassemia and Its Treatment in Iran. Pharm Sci. 422 
2012;18(3):171–6.  423 
22.  Russel S. The economic burden of illness for households in developing countries: A 424 
review of studies focusing on malaria, tuberculosis, and human immunodeficiency 425 
virus/acquired immunodeficiency syndrome. In: American Journal of Tropical 426 
Medicine and Hygiene. 2004. p. 147–55.  427 
23.  Current Status - National Hospital - Kandy, Sri Lanka [Internet]. [cited 2020 Apr 21]. 428 
Available from: http://www.kandy-hospital.health.gov.lk/about-us/current-status.html 429 
24.  Obremski T, Levin RI, Rubin DS. Statistics for Management. Am Stat. 1998;  430 
25.  Walker AER, Whynes DJK. The costing of nursing care: a study of 65 colorectal 431 
cancer patients. J Adv Nurs. 1990;15:1305–9.  432 
26.  Tan SS, Van Ineveld BM, Redekop WK, Roijen LH Van. Comparing methodologies 433 
for the allocation of overhead and capital costs to hospital services. Value Heal. 434 
2009;12(4):530–5.  435 
27.  Xu K, Evans DB, Kawabata K, Zeramdini R, Klavus J, Murray CJL. Household 436 
catastrophic health expenditure: A multicountry analysis. Lancet. 437 
2003;362(9378):111–7.  438 
28.  van Doorslaer E, O’Donnell O, Rannan-Eliya RP, Somanathan A, Adhikari SR, Garg 439 
CC, et al. Effect of payments for health care on poverty estimates in 11 countries in 440 
Asia: an analysis of household survey data. Lancet. 2006;368(9544):1357–64.  441 
29.  McIntyre D, Thiede M, Dahlgren G, Whitehead M. What are the economic 442 
consequences for households of illness and of paying for health care in low- and 443 
middle-income country contexts? Vol. 62, Social Science and Medicine. 2006. p. 858–444 
 20 
65.  445 
30.  Russell S, Gilson L. Are health services protecting the livelihoods of the urban poor in 446 
Sri Lanka? Findings from two low-income areas of Colombo. Soc Sci Med. 447 
2006;63(7):1732–44.  448 
31.  Consumer price index (2010 = 100) - Sri Lanka | Data [Internet]. [cited 2020 Apr 21]. 449 
Available from: https://data.worldbank.org/indicator/FP.CPI.TOTL?locations=LK 450 
32.  International Diabetes Federation. IDF Diabetes Atlas. 2017;  451 
33.  Sanders GD, Neumann PJ, Basu A, Brock DW, Feeny D, Krahn M, et al. 452 
Recommendations for Conduct, Methodological Practices, and Reporting of Cost-453 
effectiveness Analyses. JAMA. 2016;316(10):1093.  454 
34.  Goudge J, Gumede T, Gilson L, Russell S, Tollman SM, Mills A. Coping with the cost 455 
burdens of illness: Combining qualitative and quantitative methods in longitudinal, 456 
household research. Scand J Public Health. 2007;35:181–5.  457 
35.  Sparrow R, De Poel E Van, Hadiwidjaja G, Yumna A, Warda N, Suryahadi A. Coping 458 
with the economic consequences of ill health in Indonesia. Heal Econ (United 459 
Kingdom). 2014;23(6):719–28.  460 
36.  Department of Census and Statistics SL. Household Income and Expenditure Survey-461 
2016 Final Results. 2016.  462 
37.  Himmelstein DU, Jun M, Busse R, Chevreul K, Geissler A, Jeurissen P, et al. A 463 
comparison of hospital administrative costs in eight nations: Us costs exceed all others 464 
by far. Health Aff. 2014;  465 
38.  Patrinos H, Psacharopoulos G. Returns to education in developing countries. In: 466 
International Encyclopedia of Education. 2010. p. 305–12.  467 
 468 
